GMP Certified by UL · FDA Registered Facility · 21 CFR Part 111
Emerging Ingredients · June 18, 2026

NAD+ Precursors in 2026: NMN, NR, and Where the Category Is Going

NMN's regulatory status in the U.S. remains contested. Here's how brands are structuring product lines with NR, niacinamide, and combination stacks in the meantime.

All articles

Nicotinamide mononucleotide (NMN) sits in an unusual regulatory position in the United States: the FDA excluded it from the definition of a dietary supplement in 2022, and while enforcement has been light, the risk profile is real for a brand with meaningful ecommerce distribution.

The two most common routes brands are taking: (1) reformulate to nicotinamide riboside (NR), which remains fully compliant as a supplement ingredient, and (2) build a broader longevity stack — resveratrol, spermidine, urolithin A — where the NAD+ story is one pillar rather than the whole product.

From a manufacturing standpoint, both NMN and NR are moisture-sensitive. Capsule fills should target under 5% moisture in the blend, and finished goods should ship with desiccant packs. Tablet forms are viable but require tighter environmental controls than a standard vitamin press.

Expect the regulatory picture to keep shifting. Design your artwork to allow ingredient swaps without a full label reprint.

By LeafVentures Formulation Team
Next step

Ready to manufacture your formula?

Send us your spec — capsule, tablet, or powder. We'll respond with a quote and next steps.